The shortage of well-trained physician scientists who conduct hands-on studies in humans, particularly in the area of clinical pharmacology, is widely acknowledged. The Clinical Pharmacology Training Program at Johns Hopkins is designed specifically to address this problem. The program is centered in the Division of Clinical Pharmacology, which is jointly a unit within the Department of Medicine and the Department of Pharmacology and Molecular Sciences, in the School of Medicine. This venue is ideal for conducting research that translates basic molecular discoveries and techniques into clinical trials. The training program takes about four years to complete and includes a core curriculum in clinical pharmacology (coursework plus research rotations) as well as matriculation in the PhD track of the Graduate Training Program in Clinical Investigation. In keeping with the collective expertise of the Division faculty, research typically focuses on some aspect of anti-infective drugs. Each trainee has a Primary Mentor who is the thesis supervisor and who oversees the clinical aspects of the research project, complemented when appropriate by a Co-mentor. Participating faculty include not only those in the Division but also a group of Co-Mentors carefully chosen to reflect ongoing or foreseeable research collaborations and important teaching associations. Although there are no clinical responsibilities in the program, fellows may complete a concurrent subspecialty fellowship, typically in Infectious Diseases. The program has the regular advice and oversight of an Advisory Board comprised of distinguished clinician-scientists and outstanding clinical pharmacology educators from within and outside of Johns Hopkins. Graduates from this comprehensive, rigorous, and nurturing program are board-eligible in Clinical Pharmacology and have the skills and knowledge to step directly into an independent career at the interface of basic and clinical pharmacology.
This is a program to train physicians in the principles and practice of Clinical Pharmacology, a branch of science that focuses on the study of drugs in humans and that brings basic lab discoveries to the clinic. In a three to four year program trainees will have rigorous in-class teaching and will conduct hands-on studies of drugs in humans.
|Gupta, Amita; Mathad, Jyoti S; Abdel-Rahman, Susan M et al. (2016) Toward Earlier Inclusion of Pregnant and Postpartum Women in Tuberculosis Drug Trials: Consensus Statements From an International Expert Panel. Clin Infect Dis 62:761-9|
|Coleman, Jenell S; Fuchs, Edward; Aung, Wutyi S et al. (2016) Feasibility of radiolabeled small molecule permeability as a quantitative measure of microbicide candidate toxicity. Contraception 93:331-6|
|Conde, Marcus B; Mello, Fernanda C Q; Duarte, Rafael Silva et al. (2016) A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary Tuberculosis. PLoS One 11:e0154778|
|Hendrix, Craig W; Andrade, Adriana; Bumpus, NamandjÃ© N et al. (2016) Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066). AIDS Res Hum Retroviruses 32:32-43|
|Liu, Tao; Lewis, Tamorah; Gauda, Estelle et al. (2016) Mechanistic Population Pharmacokinetics of Morphine in Neonates With Abstinence Syndrome After Oral Administration of Diluted Tincture of Opium. J Clin Pharmacol 56:1009-18|
|Dooley, Kelly E; Phillips, Patrick P J; Nahid, Payam et al. (2016) Challenges in the clinical assessment of novel tuberculosis drugs. Adv Drug Deliv Rev 102:116-22|
|Phillips, Patrick P J; Dooley, Kelly E; Gillespie, Stephen H et al. (2016) A new trial design to accelerate tuberculosis drug development: the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP). BMC Med 14:51|
|Hoffmann, Christopher J; Cohn, Silvia; Mashabela, Fildah et al. (2016) Treatment Failure, Drug Resistance, and CD4 T-Cell Count Decline Among Postpartum Women on Antiretroviral Therapy in South Africa. J Acquir Immune Defic Syndr 71:31-7|
|Svensson, Elin M; Acharya, Chayan; Clauson, BjÃ¶rn et al. (2016) Pharmacokinetic Interactions for Drugs with a Long Half-Lifeâ€”Evidence for the Need of Model-Based Analysis. AAPS J 18:171-9|
|Jackson, Sadhana; Anders, Nicole M; Mangraviti, Antonella et al. (2016) The effect of regadenoson-induced transient disruption of the blood-brain barrier on temozolomide delivery to normal rat brain. J Neurooncol 126:433-9|
Showing the most recent 10 out of 41 publications